Literature DB >> 26718574

Acute bulbar palsy as a variant of Guillain-Barré syndrome.

Jong Kuk Kim1, Byung-Jo Kim1, Ha Young Shin1, Kyong Jin Shin1, Tai-Seung Nam1, Jeeyoung Oh1, Bum Chun Suh1, Byeol-A Yoon1, Hwan Tae Park1, So-Young Huh1, Seong-Il Oh1, Jong Seok Bae2.   

Abstract

OBJECTIVE: To categorize a syndrome manifesting as prominent acute bulbar palsy (ABP) without limb motor weakness as a variant form of Guillain-Barré syndrome (GBS) and differentiate it from Miller Fisher syndrome (MFS) and pharyngeal-cervical-brachial (PCB) variants.
METHODS: We analyzed cases of ABP without limb motor weakness based on a dataset containing clinical information and the results of antiganglioside antibodies assays for acute immune-mediated neuropathies.
RESULTS: Eleven cases with an age at onset ranging from 18 to 65 years (mean 33.8 years) were identified as ABP-plus syndrome. All of the enrolled cases manifested with ABP as the predominant symptom, and with no limb weakness. The following features accompanied ABP in order of decreasing frequency: ophthalmoplegia (n = 9, 82%), ataxia (n = 9, 82%), and facial palsy (n = 6, 55%). An enzyme-linked immunosorbent assay study disclosed that immunoglobulin G (IgG) anti-GT1a antibodies were the most frequent (n = 11), followed by IgG anti-GQ1b antibodies (n = 6).
CONCLUSIONS: We propose that ABP-plus syndrome without neck or limb weakness is a variant of GBS that is distinct from the MFS and PCB variants. The presence of IgG anti-GT1a antibodies can explain the relationships between the distinct clinical characteristics and the underlying pathomechanisms.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718574     DOI: 10.1212/WNL.0000000000002256

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Acute bulbar palsy without ophtalmoplegia associated with anti-GD3 IgM antibodies.

Authors:  Stefania Barone; Salvatore Maria Cavalli; Marco Casaletto; Aldo Quattrone; Angelo Labate
Journal:  Neurol Sci       Date:  2016-11-11       Impact factor: 3.307

Review 2.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

3.  Acute bulbar palsy plus syndrome: A rare variant of Guillain-Barre syndrome.

Authors:  Sanghamitra Ray; Prakash Chand Jain
Journal:  J Pediatr Neurosci       Date:  2016 Oct-Dec

4.  Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome.

Authors:  Jong Kuk Kim; Yoo Hwan Kim; Byeol A Yoon; Joong Yang Cho; Sun Young Oh; Ha Young Shin; Ji Soo Kim; Kee Hong Park; Sun Young Kim; Bum Chun Suh; Hung Youl Seok; Jin Hyuk Yoo; Jong Seok Bae
Journal:  J Clin Neurol       Date:  2018-07       Impact factor: 3.077

5.  Case Report: Acute Bulbar Palsy Plus Syndrome: A Guillain-Barré Syndrome Variant More Prone to Be a Subtype Than Overlap of Distinct Subtypes.

Authors:  Qian Cao; Hong Chu; Xiujuan Fu; Jiajia Yao; Zheman Xiao; Zuneng Lu
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

6.  Acute Bulbar Palsy-Plus Variant of Guillain-Barré Syndrome in a 3-Year-Old Girl.

Authors:  Saihari S Dukkipati; Daniel J Zhou; Andria M Powers; Ezequiel A Piccione; Sookyong Koh
Journal:  Child Neurol Open       Date:  2022-08-01

7.  A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.

Authors:  Serena Ruggieri; Maria Petracca; Laura De Giglio; Francesca De Luca; Costanza Giannì; Flavia Gurreri; Nikolaos Petsas; Silvia Tommasin; Carlo Pozzilli; Patrizia Pantano
Journal:  J Neurol       Date:  2021-05-03       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.